Sponsors (4)
The bill uses modest prize authority and stakeholder engagement to spur better Lyme education, diagnostics, and treatments, but its limited funding and lack of mandates mean benefits may be modest, uneven, and could divert attention or resources from other priorities while costing taxpayers a small appropriation.
People at risk for or living with Lyme disease: faster development of improved prevention, diagnostics, and treatments driven by federal prize incentives and stakeholder-focused policy.
People with Lyme disease: earlier diagnosis and treatment from improved public education, awareness, and more patient-centered diagnostics, reducing time to diagnosis and unnecessary care.
Researchers and startups: access to non-dilutive prize awards that lower commercialization barriers and increase visibility for promising solutions.
Patients, researchers, and health systems: promised actions may not materialize or be effective because parts of the bill create no mandates and the only appropriation is a modest $5 million that is likely insufficient for later-stage development or commercialization.
Small community groups and patient-advocate organizations: prize competitions may favor well-resourced teams, leaving less-resourced stakeholders without awards or influence.
Patients and public-health priorities: a heightened focus on Lyme could divert limited research attention and resources from other infectious diseases if not appropriately prioritized.
Based on analysis of 3 sections of legislative text.
Authorizes $5 million for HHS to run prize competitions and states a nonbinding policy to promote stakeholder engagement, education, and better Lyme disease diagnostics.
Introduced February 11, 2026 by Christopher Henry Smith · Last progress February 11, 2026
Authorizes $5,000,000 for the Department of Health and Human Services to run prize competitions aimed at accelerating prevention, diagnosis, and treatment innovations for Lyme disease, and sets a nonbinding federal policy to encourage stakeholder engagement, public education, and development of rapid, patient-focused diagnostics. One section only provides a short title and carries no operative policy; the funding authorization is limited in scope and does not itself appropriate funds or create new regulatory mandates.